Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Reducing protein oxidation reverses lung fibrosis.

Anathy V, Lahue KG, Chapman DG, Chia SB, Casey DT, Aboushousha R, van der Velden JLJ, Elko E, Hoffman SM, McMillan DH, Jones JT, Nolin JD, Abdalla S, Schneider R, Seward DJ, Roberson EC, Liptak MD, Cousins ME, Butnor KJ, Taatjes DJ, Budd RC, Irvin CG, Ho YS, Hakem R, Brown KK, Matsui R, Bachschmid MM, Gomez JL, Kaminski N, van der Vliet A, Janssen-Heininger YMW.

Nat Med. 2018 Jul 9. doi: 10.1038/s41591-018-0090-y. [Epub ahead of print]

PMID:
29988126
2.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis: The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2018 Jul 9. doi: 10.1164/rccm.201803-0444PP. [Epub ahead of print]

PMID:
29986154
3.

The NHLBI LAM Registry: Prognostic physiological and radiological biomarkers emerge from a 15-year prospective longitudinal analysis.

Gupta N, Lee HS, Ryu JH, Taveira-DaSilva AM, Beck GJ, Lee JC, McCarthy K, Finlay GA, Brown KK, Ruoss SJ, Avila NA, Moss J, McCormack FX; NHLBI LAM Registry Group.

Chest. 2018 Jun 22. pii: S0012-3692(18)30934-6. doi: 10.1016/j.chest.2018.06.016. [Epub ahead of print]

PMID:
29940164
4.

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials.

Swigris JJ, Wilson H, Esser D, Conoscenti CS, Stansen W, Kline Leidy N, Brown KK.

BMJ Open Respir Res. 2018 May 18;5(1):e000278. doi: 10.1136/bmjresp-2018-000278. eCollection 2018.

5.

Tumor immune evasion arises through loss of TNF sensitivity.

Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, Pijpers L, Michie J, Brown KK, Knight DA, Sutton V, Beavis PA, Voskoboinik I, Darcy PK, Silke J, Trapani JA, Johnstone RW, Oliaro J.

Sci Immunol. 2018 May 18;3(23). pii: eaar3451. doi: 10.1126/sciimmunol.aar3451.

PMID:
29776993
6.

What's in a name? That which we call IPF, by any other name would act the same.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group.

Eur Respir J. 2018 May 17;51(5). pii: 1800692. doi: 10.1183/13993003.00692-2018. Print 2018 May.

PMID:
29773608
7.

The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis.

Okamoto T, Mathai SK, Hennessy CE, Hancock LA, Walts AD, Stefanski AL, Brown KK, Lynch DA, Cosgrove GP, Groshong SD, Cool CD, Schwarz MI, Banda NK, Thurman JM, Yang IV, Holers VM, Schwartz DA.

Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L1-L10. doi: 10.1152/ajplung.00395.2017. Epub 2018 Mar 22.

PMID:
29565179
8.

Cavitary Lung Diseases: A Clinical-Radiologic Algorithmic Approach.

Gafoor K, Patel S, Girvin F, Gupta N, Naidich D, Machnicki S, Brown KK, Mehta A, Husta B, Ryu JH, Sarosi GA, Franquet T, Verschakelen J, Johkoh T, Travis W, Raoof S.

Chest. 2018 Jun;153(6):1443-1465. doi: 10.1016/j.chest.2018.02.026. Epub 2018 Mar 6. Review.

PMID:
29518379
9.

Youth empowerment implementation project evaluation results: A program designed to improve the health and well-being of low-income African-American adolescents.

Lewis RK, Lee FA, Brown KK, LoCurto J, Stowell D, Maryman J, Lovelady T, Williams G, Morris DM, McNair T.

J Prev Interv Community. 2018 Jan-Mar;46(1):28-42. doi: 10.1080/10852352.2018.1385954.

PMID:
29281596
10.

Is Timing of Enrollment Associated with Birth Outcomes? Findings from a Healthy Start Program in Kansas.

Brown KK, Johnson C, Spainhower M, Phillips NF, Maryman J.

Matern Child Health J. 2017 Dec;21(Suppl 1):25-31. doi: 10.1007/s10995-017-2405-x.

11.

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU.

Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review.

12.

Reply: Improving Care for Patients with Interstitial Lung Disease, Using Machine Learning, Requires Transparency and Reproducibility.

Kennedy GC, Barth NM, Walsh PS, Huang J, Pankratz DG, Choi Y, Fedorowicz GM, Anderson JD, Raghu G, Martinez FJ, Colby TV, Lynch DA, Brown KK, Groshong SD, Myers JL, Flaherty KR, Steele MP.

Ann Am Thorac Soc. 2017 Dec;14(12):1864-1865. doi: 10.1513/AnnalsATS.201708-654LE. No abstract available.

PMID:
29058451
13.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

14.

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.

Kondoh Y, Cottin V, Brown KK.

Eur Respir Rev. 2017 Sep 27;26(145). pii: 170050. doi: 10.1183/16000617.0050-2017. Print 2017 Sep 30. Erratum in: Eur Respir Rev. 2018 Apr 13;27(148):.

15.

Cutaneous eruption associated with Streptococcus dysgalactiae (group C Streptococcus) bacteremia.

Ashchyan HJ, Brown KK.

JAAD Case Rep. 2017 Aug 12;3(5):373-375. doi: 10.1016/j.jdcr.2017.04.004. eCollection 2017 Sep. No abstract available.

16.

Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).

Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS™ trial investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29.

17.

Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning.

Pankratz DG, Choi Y, Imtiaz U, Fedorowicz GM, Anderson JD, Colby TV, Myers JL, Lynch DA, Brown KK, Flaherty KR, Steele MP, Groshong SD, Raghu G, Barth NM, Walsh PS, Huang J, Kennedy GC, Martinez FJ.

Ann Am Thorac Soc. 2017 Nov;14(11):1646-1654. doi: 10.1513/AnnalsATS.201612-947OC.

PMID:
28640655
18.

Presence of Air Trapping and Mosaic Attenuation on Chest Computed Tomography Predicts Survival in Chronic Hypersensitivity Pneumonitis.

Chung JH, Zhan X, Cao M, Koelsch TL, Manjarres DCG, Brown KK, Lynch DA, Russell G, Fernández Pérez ER.

Ann Am Thorac Soc. 2017 Oct;14(10):1533-1538. doi: 10.1513/AnnalsATS.201701-035OC.

PMID:
28513215
19.

AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.

Kaner RJ, Brown KK, Martinez FJ.

Am J Respir Crit Care Med. 2017 May 1;195(9):1104-1107. doi: 10.1164/rccm.201703-0584ED. No abstract available.

20.

High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival.

Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, Keith RC, Janssen WJ, Goldstein BL, Lynch DA, Brown KK, Swigris JJ, Solomon JJ.

Respir Med. 2017 May;126:100-104. doi: 10.1016/j.rmed.2017.03.027. Epub 2017 Mar 30.

PMID:
28427540
21.

Rare Genetic Variants in PARN Are Associated with Pulmonary Fibrosis in Families.

Kropski JA, Reiss S, Markin C, Brown KK, Schwartz DA, Schwarz MI, Loyd JE, Phillips JA 3rd, Blackwell TS, Cogan JD.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1481-1484. doi: 10.1164/rccm.201703-0635LE. No abstract available.

PMID:
28414520
22.

Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.

Brown KK, Spinelli JB, Asara JM, Toker A.

Cancer Discov. 2017 Apr;7(4):391-399. doi: 10.1158/2159-8290.CD-16-0611. Epub 2017 Mar 2. Erratum in: Cancer Discov. 2017 Jul;7(7):782.

23.

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis.

Swigris JJ, Esser D, Wilson H, Conoscenti CS, Schmidt H, Stansen W, Leidy NK, Brown KK.

Eur Respir J. 2017 Jan 18;49(1). pii: 1601788. doi: 10.1183/13993003.01788-2016. Print 2017 Jan.

24.

An Evaluation of a Competency-Based Public Health Training Program for Public Health Professionals in Kansas.

Brown KK, Maryman J, Collins T.

J Public Health Manag Pract. 2017 Sep/Oct;23(5):447-453. doi: 10.1097/PHH.0000000000000513.

PMID:
28079642
25.

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, Wells AU, Whelan TP, Wuyts W, Moreau E, Patterson SD, Smith V, Bayly S, Chien JW, Gong Q, Zhang JJ, O'Riordan TG.

Lancet Respir Med. 2017 Jan;5(1):22-32. doi: 10.1016/S2213-2600(16)30421-0. Epub 2016 Dec 7.

PMID:
27939076
26.

Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.

Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A.

Respir Med. 2016 Oct;119:150-154. doi: 10.1016/j.rmed.2016.09.002. Epub 2016 Sep 3.

PMID:
27692137
27.

Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J; ATS/JRS Committee on Lymphangioleiomyomatosis.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61. doi: 10.1164/rccm.201607-1384ST.

28.

Selenoprotein H is an essential regulator of redox homeostasis that cooperates with p53 in development and tumorigenesis.

Cox AG, Tsomides A, Kim AJ, Saunders D, Hwang KL, Evason KJ, Heidel J, Brown KK, Yuan M, Lien EC, Lee BC, Nissim S, Dickinson B, Chhangawala S, Chang CJ, Asara JM, Houvras Y, Gladyshev VN, Goessling W.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):E5562-71. doi: 10.1073/pnas.1600204113. Epub 2016 Sep 1.

29.

Surgical Lung Biopsy for Interstitial Lung Diseases.

Raj R, Raparia K, Lynch DA, Brown KK.

Chest. 2017 May;151(5):1131-1140. doi: 10.1016/j.chest.2016.06.019. Epub 2016 Jul 26. Review.

PMID:
27471113
30.

Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth.

Cox AG, Hwang KL, Brown KK, Evason K, Beltz S, Tsomides A, O'Connor K, Galli GG, Yimlamai D, Chhangawala S, Yuan M, Lien EC, Wucherpfennig J, Nissim S, Minami A, Cohen DE, Camargo FD, Asara JM, Houvras Y, Stainier DYR, Goessling W.

Nat Cell Biol. 2016 Aug;18(8):886-896. doi: 10.1038/ncb3389. Epub 2016 Jul 18.

31.

Exploring the Experience of Life Stress Among Black Women with a History of Fetal or Infant Death: a Phenomenological Study.

Brown KK, Lewis RK, Baumgartner E, Schunn C, Maryman J, LoCurto J.

J Racial Ethn Health Disparities. 2017 Jun;4(3):484-496. doi: 10.1007/s40615-016-0250-z. Epub 2016 Jul 12.

PMID:
27406594
32.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ.

Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75. doi: 10.1164/rccm.201604-0801CI. Review.

33.

COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.

Brown KK.

Chest. 2016 Aug;150(2):276-8. doi: 10.1016/j.chest.2016.04.036. Epub 2016 Jun 9. No abstract available.

PMID:
27292046
34.

Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis.

Jones MG, Fabre A, Schneider P, Cinetto F, Sgalla G, Mavrogordato M, Jogai S, Alzetani A, Marshall BG, O'Reilly KM, Warner JA, Lackie PM, Davies DE, Hansell DM, Nicholson AG, Sinclair I, Brown KK, Richeldi L.

JCI Insight. 2016 Apr 21;1(5). pii: e86375.

35.

Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis.

Olson AL, Brown KK, Swigris JJ.

Patient Relat Outcome Meas. 2016 May 17;7:29-35. doi: 10.2147/PROM.S74857. eCollection 2016. Review.

36.

Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia.

Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, Schwartz DA.

BMC Genet. 2016 Jun 7;17(1):74. doi: 10.1186/s12863-016-0377-2.

37.

Mortality Related to Surgical Lung Biopsy in Patients with Interstitial Lung Disease. The Devil Is in the Denominator.

Raj R, Brown KK.

Am J Respir Crit Care Med. 2016 May 15;193(10):1082-4. doi: 10.1164/rccm.201512-2488ED. No abstract available.

PMID:
27174478
38.

Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease.

Mannina A, Chung JH, Swigris JJ, Solomon JJ, Huie TJ, Yunt ZX, Truong TQ, Brown KK, Achcar RD, Olson AL, Cox CW, Kligerman SJ, Curran-Everett D, Fernández Pérez ER.

Ann Am Thorac Soc. 2016 Jul;13(7):1042-9. doi: 10.1513/AnnalsATS.201511-728OC.

PMID:
27064856
39.

An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research.

White ES, Borok Z, Brown KK, Eickelberg O, Guenther A, Jenkins RG, Kolb M, Martinez FJ, Roman J, Sime P; American Thoracic Society Respiratory Cell and Molecular Biology Assembly Working Group on Pulmonary Fibrosis.

Am J Respir Crit Care Med. 2016 Apr 1;193(7):792-800. doi: 10.1164/rccm.201602-0254ST.

40.

FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.

Raghu G, Scholand MB, de Andrade J, Lancaster L, Mageto Y, Goldin J, Brown KK, Flaherty KR, Wencel M, Wanger J, Neff T, Valone F, Stauffer J, Porter S.

Eur Respir J. 2016 May;47(5):1481-91. doi: 10.1183/13993003.01030-2015. Epub 2016 Mar 10.

41.

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK.

Respir Med. 2016 Apr;113:74-9. doi: 10.1016/j.rmed.2016.02.001. Epub 2016 Feb 3.

42.

Development of the chemical exposure monitor with indoor positioning (CEMWIP) for workplace VOC surveys.

Brown KK, Shaw PB, Mead KR, Kovein RJ, Voorhees RT, Brandes AR.

J Occup Environ Hyg. 2016;13(6):401-12. doi: 10.1080/15459624.2015.1125488.

43.

Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users.

Cao M, Wamboldt FS, Brown KK, Hickman J, Olson AL, Solomon JJ, Swigris JJ.

Multidiscip Respir Med. 2015 Nov 30;10:37. doi: 10.1186/s40248-015-0035-y. eCollection 2015.

44.

Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis.

Mathai SK, Pedersen BS, Smith K, Russell P, Schwarz MI, Brown KK, Steele MP, Loyd JE, Crapo JD, Silverman EK, Nickerson D, Fingerlin TE, Yang IV, Schwartz DA.

Am J Respir Crit Care Med. 2016 May 15;193(10):1151-60. doi: 10.1164/rccm.201509-1863OC.

45.

Advances in the treatment of idiopathic pulmonary fibrosis.

Sergew A, Brown KK.

Expert Opin Emerg Drugs. 2015;20(4):537-52. doi: 10.1517/14728214.2015.1102886. Epub 2015 Dec 2. Review.

PMID:
26629731
46.

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.

Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ.

Eur Respir J. 2016 Feb;47(2):588-96. doi: 10.1183/13993003.00357-2015. Epub 2015 Nov 19.

47.

Relationship between gene expression and lung function in Idiopathic Interstitial Pneumonias.

Steele MP, Luna LG, Coldren CD, Murphy E, Hennessy CE, Heinz D, Evans CM, Groshong S, Cool C, Cosgrove GP, Brown KK, Fingerlin TE, Schwarz MI, Schwartz DA, Yang IV.

BMC Genomics. 2015 Oct 26;16:869. doi: 10.1186/s12864-015-2102-3.

48.

CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.

Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, Lancaster L, Gibson KF, Haddad T, Agarwal P, Mack M, Dasgupta B, Nnane IP, Flavin SK, Barnathan ES.

Eur Respir J. 2015 Dec;46(6):1740-50. doi: 10.1183/13993003.01558-2014. Epub 2015 Oct 22.

49.

Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 1,044 Chinese Patients.

Hu Y, Wang LS, Wei YR, Du SS, Du YK, He X, Li N, Zhou Y, Li QH, Su YL, Zhang F, Shen L, Weng D, Brown KK, Li HP.

Chest. 2016 Jan;149(1):201-8. doi: 10.1378/chest.15-1145. Epub 2016 Jan 6.

PMID:
26447566
50.

Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.

Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, Wells AU, Schmidt SL, Martinez FJ, Flaherty KR.

Chest. 2016 Feb;149(2):491-498. doi: 10.1378/chest.15-0530. Epub 2016 Jan 12.

Supplemental Content

Loading ...
Support Center